- News & Analysis
- Home
- Latest News
- Reports
- Podcasts
- The CVC Funding Round Database
- The CVC Directory
- University
- Video
- Subscribe
- Newsletters
- Job Postings
- Events
Page 963
Novo newly into Denator
The other co-lead and new investor was Almi Invest, which joined existing investors including T-bolaget, Wikow Ventures, SGP Group and Servisen.
Apr 1, 2012Nantworks walks on to Strand deal
Since 2007, Soon-Shiong, Los Angeles' richest man after forming Abraxis BioScience, has funded more than 35 companies spanning healthcare, education, science, and technology before in September last year he set up NantWorks, which also runs NantAccelerator to provide seed funding and resources to support start-ups.
Apr 1, 2012Micromedic backs BioMarCare
BioMarCare is a portfolio company of Hadasit Bio-Holdings, a publicly traded holding company for businesses using intellectual property developed and owned by Israel's Hadassah University Hospital.
Apr 1, 2012Hadassah University Hospital finds support
BioMarCare is a portfolio company of Hadasit Bio-Holdings, a publicly traded holding company for businesses using intellectual property developed and owned by Israel's Hadassah University Hospital.
Apr 1, 2012Healthcare becomes testing ground
The past few weeks has seen indications for how corporations will work with venture capital peers, charities and endowments, government-sponsored funds and others, including secodnaries and family offices, to create syndicates that can support the next generation of entrepreneurial ideas, academics and companies.
Apr 1, 2012Omeros gains Gray's knowledge
Previously, Gray was chief executive of Nura, a privately held biotechnology company acquired by Omeros in 2006.
Mar 30, 2012Constellation appoints Keith Dionne CEO
Repeat entrepreneur Dionne joins the molecular therapeutics company, backed by Genentech and GlaxoSmithKline's corporate venturing unit, which was founded by three academics in the field of epigenetics.
Mar 28, 2012Royal DSM beefs up IQ
Royal DSM invests again in "super-bug" treatment company IQ Therapeutics.
Mar 28, 2012About us
GCV provides the global corporate venturing community and their ecosystem partners with the information, insights and access needed to drive impactful open innovation. Across our three services - News & Analysis, Community & Events, and the GCV Institute - we create a network-rich environment for global innovation and capital to meet and thrive. At the heart of our community sits our membership, providing privileged access to all our services and resources.
Navigation
test regLogin
Not yet subscribed?
We use cookies to enhance your browsing experience and analyse our traffic. By clicking "Accept All", you consent to our use of cookies. Accept Read MorePrivacy & Cookies PolicyPrivacy Overview
This website uses cookies to improve your experience while you navigate through the website. Out of these, the cookies that are categorized as necessary are stored on your browser as they are essential for the working of basic functionalities of the website. We also use third-party cookies that help us analyze and understand how you use this website. These cookies will be stored in your browser only with your consent. You also have the option to opt-out of these cookies. But opting out of some of these cookies may affect your browsing experience.Necessary cookies are absolutely essential for the website to function properly. This category only includes cookies that ensures basic functionalities and security features of the website. These cookies do not store any personal information.Any cookies that may not be particularly necessary for the website to function and is used specifically to collect user personal data via analytics, ads, other embedded contents are termed as non-necessary cookies. It is mandatory to procure user consent prior to running these cookies on your website.


